Pirenoxine ophthalmic solution, an anticataract drug for human use , was tested for its effectiveness in the treatment of senile incipient cataract in dogs . Of 18 cases treated with the drug, 13 (72.2%) cases responded favorably resulting in improved lens opacity or delayed progress of the disease . Hyperemia and epiphora, both being local sensitive symptoms, were obsereved in one case . Improved lens opacity was noticeable after medication for 81.6 days on average, and the effect was pronounced in younger cases with cortical cataract.-Key Words: anticataract drug , dog, ophthalmic solution, pirenoxine, senile incipient cataract 1) AUGUSTEYN RC:
